Search

The hippocampus is a brain area fundamental for cognitive functions, such as learning, memory, spatial navigation and emotion regulation, and is mainly affected in Alzheimer’s disease (AD). AD is an irreversible neurodegenerative disease, characterized by pathological protein aggregations and cognitive impairments. To date, there is no treatment for Alzheimer’s disease. The search for a therapy is urgently needed to alleviate the suffering of patients and relieve the burden on society. Neural stem cells (NSCs) in the hippocampal neurogenic niche sustain continuous neurogenesis in adulthood. Adult hippocampal neurogenesis (AHN) is functionally associated with many cognitive and emotional functions in humans and rodents. In particular, hippocampal neurogenesis is impaired in AD patients and AD mouse models and may be a putative therapeutic target for curing AD. In my project, endogenous hippocampal neurogenesis is manipulated in the 3xTg AD mouse model by a chronic, genetically-driven expansion of hippocampal NSCs. Exploiting intrinsic NSCs potential to generate newborn neurons increases the neurogenesis in 3xTg AD mice. The boosted neurogenesis ameliorates the anxiety-like behavior, improves spatial navigational performances and restores the connectivity of the hippocampal network in AD. Altogether, this study demonstrates the beneficial effect of enhancing neurogenesis by exploiting the endogenous NSCs reserve to rescue AD phenotypes and elucidates the functional contribution of neurogenesis to learning and memory. The findings support and highlight the therapeutic potential of enhancing neurogenesis in the treatments of neurodegenerative diseases.

The neurodegenerative disorder Parkinson's Disease (PD) represents both a major socioeco-nomic challenge and an individual burden for many patients. Despite major efforts, neither satisfactory explanations of the pathogenesis of PD, nor disease-modifying drugs have been developed to date. Mutations of the multidomain kinase LRRK2 represent the overall most common cause of he-reditary PD. Furthermore, LRRK2 mutations have been linked to dysregulations of the immune system such as inflammatory bowel disease, cancer, or the susceptibility towards mycobacte-rial infections. Several pathogenic point mutations have been identified that – directly or indi-rectly – lead to a pathological gain-of-function of the protein’s kinase domain. Despite recent advances, the physiological functions of LRRK2, as well as the underlying processes of LRRK2-mediated pathologies, remain largely unknown. Much research effort has aimed at generating reliable animal models for the study of LRRK2. Nevertheless, neither loss-of-function of the gene, nor overexpression of normal or mutant LRRK2, has yielded definitive results. Previous work from our research group on zebrafish (Danio rerio) has generated two genetic lrrk2 knock-out lines using different mutagenesis strat-egies: lrrk2TILLING and lrrk2CRISPR (Ahrendt, 2011; Suzzi, 2017). These studies’ results were par-tially contradictory, and the described phenotypes were not stable. Whilst this previous work investigated lrrk2 loss-of-function, so far, no genetic knock-in line carrying one of the multiple known pathogenic lrrk2 mutations, has been reported in zebrafish. Therefore, this work aimed to further investigate the effects of Lrrk2-deficiency in zebrafish and to establish a genetic knock-in of the common pathogenic G2019S substitution to model the genotype of PD patients more accurately. A variety of methods was applied to achieve these aims. Immunohistochemistry and conventional histology studies were performed on zebrafish brains and k, Die neurodegenerative Erkrankung Morbus Parkinson (Idiopathisches Parkinson-Syndrom, IPS) stellt sowohl eine individuelle Belastung für betroffene Menschen als auch eine große sozio-ökonomische Herausforderung für die Gesellschaft dar. Trotz großer Anstrengungen konnten bisher weder zufriedenstellende pathophysiologische Erklärungen des IPS, noch krankheits-modulierende Medikamente entwickelt werden. Mutationen der Kinase LRRK2 sind die insgesamt häufigste Ursache für erbliche Parkinson-Syndrome. Darüber hinaus wurden LRRK2-Mutationen mit immundysregulatorischen Syndro-men wie chronisch-entzündlichen Darmerkrankungen, Malignomen oder der Anfälligkeit ge-genüber Mykobakterien-Infektionen in Verbindung gebracht. Verschiedene pathogene Punktmutationen von LRRK2 sind bekannt. Diese führen – direkt oder indirekt – zu einer pa-thologischen Überaktivierung seiner Kinasedomäne. Trotz jüngster Fortschritte in der For-schung sind die Funktionen von LRRK2 und die Prozesse, die zu den LRRK2-vermittelten Pathologien führen, weiterhin weitgehend unbekannt. Viele Studien haben sich um die Entwicklung zuverlässiger Tiermodelle für die Untersuchung von LRRK2 bemüht. Dennoch haben weder die Untersuchung eines Gen-Funktionsverlusts noch die Überexpression von normalem oder mutiertem LRRK2 bislang zu eindeutigen Ergeb-nissen geführt. Frühere Arbeiten unserer Arbeitsgruppe haben in Zebrafischen (Zebrabärbling, Danio rerio) zwei genetische lrrk2-Knockout-Linien mit unterschiedlichen Mutagenesestrate-gien erzeugt: lrrk2TILLING und lrrk2CRISPR (Ahrendt, 2011; Suzzi, 2017). Die Ergebnisse dieser Studien widersprachen sich teilweise, und die beschriebenen Phänotypen waren nicht stabil reproduzierbar. Während alle bisherigen Arbeiten einen Funktionsverlust von Lrrk2 untersuch-ten, wurde bisher noch keine genetische Knock-in-Linie im Zebrafisch publiziert, die eine der zahlreichen bekannten pathogen-überaktivierenden LRRK2-Mutationen trägt. Ziel dieser Arbeit war es daher zum einen, die Auswir